<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JTO Clin Res Rep</journal-id><journal-id journal-id-type="iso-abbrev">JTO Clin Res Rep</journal-id><journal-id journal-id-type="pmc-domain-id">4097</journal-id><journal-id journal-id-type="pmc-domain">jtocrr</journal-id><journal-title-group><journal-title>JTO Clinical and Research Reports</journal-title></journal-title-group><issn pub-type="epub">2666-3643</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10209333</article-id><article-id pub-id-type="pmcid-ver">PMC10209333.1</article-id><article-id pub-id-type="pmcaid">10209333</article-id><article-id pub-id-type="pmcaiid">10209333</article-id><article-id pub-id-type="pmid">37250506</article-id><article-id pub-id-type="doi">10.1016/j.jtocrr.2023.100508</article-id><article-id pub-id-type="pii">S2666-3643(23)00047-4</article-id><article-id pub-id-type="publisher-id">100508</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With <italic toggle="yes">ALK</italic>-Positive NSCLC in Japan</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Goto</surname><given-names initials="Y">Yasushi</given-names></name><degrees>MD, PhD</degrees><email>ygoto@ncc.go.jp</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">&#8727;</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Kenmotsu</surname><given-names initials="H">Hirotsugu</given-names></name><degrees>MD, PhD</degrees><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Tamiya</surname><given-names initials="M">Motohiro</given-names></name><degrees>MD</degrees><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Murakami</surname><given-names initials="S">Shuji</given-names></name><degrees>MD</degrees><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Kurata</surname><given-names initials="T">Takayasu</given-names></name><degrees>MD</degrees><xref rid="aff5" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au6"><name name-style="western"><surname>Yanagitani</surname><given-names initials="N">Noriko</given-names></name><degrees>MD</degrees><xref rid="aff6" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au7"><name name-style="western"><surname>Taniguchi</surname><given-names initials="H">Hirokazu</given-names></name><degrees>MD, PhD</degrees><xref rid="aff7" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au8"><name name-style="western"><surname>Kuyama</surname><given-names initials="S">Shoichi</given-names></name><degrees>MD, PhD</degrees><xref rid="aff8" ref-type="aff">h</xref></contrib><contrib contrib-type="author" id="au9"><name name-style="western"><surname>Shimizu</surname><given-names initials="J">Junichi</given-names></name><degrees>MD, PhD</degrees><xref rid="aff9" ref-type="aff">i</xref></contrib><contrib contrib-type="author" id="au10"><name name-style="western"><surname>Yokoyama</surname><given-names initials="T">Toshihide</given-names></name><degrees>MD</degrees><xref rid="aff10" ref-type="aff">j</xref></contrib><contrib contrib-type="author" id="au11"><name name-style="western"><surname>Shimada</surname><given-names initials="N">Naoko</given-names></name><degrees>MD, PhD</degrees><xref rid="aff11" ref-type="aff">k</xref></contrib><contrib contrib-type="author" id="au12"><name name-style="western"><surname>Maeda</surname><given-names initials="T">Tadashi</given-names></name><degrees>MD</degrees><xref rid="aff12" ref-type="aff">l</xref></contrib><contrib contrib-type="author" id="au13"><name name-style="western"><surname>Tamiya</surname><given-names initials="A">Akihiro</given-names></name><degrees>MD</degrees><xref rid="aff13" ref-type="aff">m</xref></contrib><contrib contrib-type="author" id="au14"><name name-style="western"><surname>Uchiyama</surname><given-names initials="A">Ayumi</given-names></name><degrees>MD</degrees><xref rid="aff14" ref-type="aff">n</xref></contrib><contrib contrib-type="author" id="au15"><name name-style="western"><surname>Imaizumi</surname><given-names initials="K">Kazuyoshi</given-names></name><degrees>MD</degrees><xref rid="aff15" ref-type="aff">o</xref></contrib><contrib contrib-type="author" id="au16"><name name-style="western"><surname>Takahama</surname><given-names initials="T">Takayuki</given-names></name><degrees>MD, PhD</degrees><xref rid="aff16" ref-type="aff">p</xref></contrib><contrib contrib-type="author" id="au17"><name name-style="western"><surname>Kato</surname><given-names initials="T">Terufumi</given-names></name><degrees>MD</degrees><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au18"><name name-style="western"><surname>Hayashi</surname><given-names initials="H">Hidetoshi</given-names></name><degrees>MD</degrees><xref rid="aff16" ref-type="aff">p</xref></contrib><contrib contrib-type="author" id="au19"><name name-style="western"><surname>Shiraiwa</surname><given-names initials="N">Naoko</given-names></name><degrees>MSc</degrees><xref rid="aff17" ref-type="aff">q</xref></contrib><contrib contrib-type="author" id="au20"><name name-style="western"><surname>Toyoizumi</surname><given-names initials="S">Shigeyuki</given-names></name><degrees>MSc</degrees><xref rid="aff18" ref-type="aff">r</xref></contrib><contrib contrib-type="author" id="au21"><name name-style="western"><surname>Kikkawa</surname><given-names initials="H">Hironori</given-names></name><degrees>PhD</degrees><xref rid="aff17" ref-type="aff">q</xref></contrib><contrib contrib-type="author" id="au22"><name name-style="western"><surname>Thomaidou</surname><given-names initials="D">Despina</given-names></name><degrees>MSc</degrees><xref rid="aff19" ref-type="aff">s</xref></contrib><contrib contrib-type="author" id="au23"><name name-style="western"><surname>Nishio</surname><given-names initials="M">Makoto</given-names></name><degrees>MD, PhD</degrees><xref rid="aff6" ref-type="aff">f</xref></contrib><aff id="aff1"><label>a</label>National Cancer Center Hospital, Tokyo, Japan</aff><aff id="aff2"><label>b</label>Shizuoka Cancer Center, Shizuoka, Japan</aff><aff id="aff3"><label>c</label>Osaka International Cancer Institute, Osaka, Japan</aff><aff id="aff4"><label>d</label>Kanagawa Cancer Center, Kanagawa, Japan</aff><aff id="aff5"><label>e</label>Kansai Medical University Hospital, Osaka, Japan</aff><aff id="aff6"><label>f</label>Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan</aff><aff id="aff7"><label>g</label>Toyama Central Hospital, Toyama, Japan</aff><aff id="aff8"><label>h</label>Iwakuni Clinical Center, Yamaguchi, Japan</aff><aff id="aff9"><label>i</label>Aichi Cancer Center Hospital, Aichi, Japan</aff><aff id="aff10"><label>j</label>Kurashiki Central Hospital, Okayama, Japan</aff><aff id="aff11"><label>k</label>Juntendo University, Tokyo, Japan</aff><aff id="aff12"><label>l</label>Yamaguchi Ube Medical Center, Yamaguchi, Japan</aff><aff id="aff13"><label>m</label>Kinki-Chuo Chest Medical Center, Osaka, Japan</aff><aff id="aff14"><label>n</label>Jichi Medical University, Tochigi, Japan</aff><aff id="aff15"><label>o</label>Fujita Health University, Aichi, Japan</aff><aff id="aff16"><label>p</label>Kindai University, Osaka, Japan</aff><aff id="aff17"><label>q</label>Pfizer Japan, Tokyo, Japan</aff><aff id="aff18"><label>r</label>Pfizer R&amp;D, Tokyo, Japan</aff><aff id="aff19"><label>s</label>Pfizer Inc., Athens, Greece</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8727;</label>Corresponding author. Address for correspondence: Yasushi Goto, MD, PhD, Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. <email>ygoto@ncc.go.jp</email></corresp></author-notes><pub-date pub-type="collection"><month>5</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>24</day><month>3</month><year>2023</year></pub-date><volume>4</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">434648</issue-id><elocation-id>100508</elocation-id><history><date date-type="received"><day>4</day><month>1</month><year>2023</year></date><date date-type="rev-recd"><day>16</day><month>3</month><year>2023</year></date><date date-type="accepted"><day>21</day><month>3</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>24</day><month>03</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>26</day><month>05</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-05-30 14:25:09.650"><day>30</day><month>05</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 The Authors</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><sec><title>Introduction</title><p>Lorlatinib is an ALK tyrosine kinase inhibitor approved in Japan for the treatment of advanced <italic toggle="yes">ALK</italic>+ NSCLC. There has been little evidence about lorlatinib efficacy after first-line (1L) alectinib in clinical practice in Japan.</p></sec><sec><title>Methods</title><p>We retrospectively analyzed patients with advanced <italic toggle="yes">ALK</italic>+ NSCLC previously treated with 1L alectinib at multiple sites in Japan. Primary objectives were to collect patient demographics at baseline and estimate time to treatment failure (TTF) with second-line (2L) or third-line (3L) or later line (&#8805;3L) lorlatinib treatment. Secondary objectives included objective response rate (ORR) with lorlatinib, reason for discontinuation and time to last treatment failure with lorlatinib, TTF and ORR of alectinib, and combined TTF.</p></sec><sec><title>Results</title><p>Among the 51 patients included in the study, 29 (56.9%) received 2L and 22 (43.1%) received &#8805;3L lorlatinib treatment. At lorlatinib initiation, brain metastases were reported in 25 patients (49.0%), and 32 (62.7%) had an Eastern Cooperative Oncology Group performance status of 0 or 1. Median TTF with lorlatinib was 11.1 months (95% confidence interval [CI]: 4.6&#8211;13.8) in any line, 10.8 months (95% CI: 3.9&#8211;13.8) in 2L, and 11.5 months (95% CI: 2.9&#8211;not reached) in &#8805;3L. Median TTF was 11.5 months (95% CI: 3.9&#8211;not reached) in patients with brain metastases at lorlatinib initiation and 9.9 months (95% CI: 4.3&#8211;13.8) in patients without brain metastases. ORR was 35.7% with any-line lorlatinib treatment.</p></sec><sec><title>Conclusions</title><p>Patient characteristics and efficacy were comparable with previous reports when lorlatinib was given after 1L alectinib in patients with <italic toggle="yes">ALK</italic>+ NSCLC.</p></sec></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Non&#8211;small cell lung cancer</kwd><kwd>Anaplastic lymphoma kinase</kwd><kwd>Tyrosine kinase inhibitor</kwd><kwd>Lorlatinib</kwd><kwd>Real-world data</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p id="p0010">Targeted ALK tyrosine kinase inhibitor (TKI) use for treatment of NSCLC varies across geographic locations.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> Currently, in Japan, alectinib, a second-generation ALK TKI, is recommended in the first-line (1L) treatment setting for <italic toggle="yes">ALK</italic>+ NSCLC, according to the 2021 Japanese Lung Cancer Society treatment guidelines.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> This recommendation was based on the results of the phase 3 J-ALEX and ALEX studies that found superior efficacy and lower toxicity with alectinib compared with crizotinib for 1L treatment of <italic toggle="yes">ALK</italic>+ NSCLC.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref><sup>,</sup><xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> Nevertheless, many patients develop resistance to second-generation ALK TKIs owing to several secondary mutations.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> In Japan, after disease progression on 1L treatment with alectinib for <italic toggle="yes">ALK</italic>+ NSCLC, treatment recommendations include lorlatinib or brigatinib.</p><p id="p0015">Lorlatinib is a third-generation, highly potent ALK TKI approved in Japan in September 2018 for the treatment of <italic toggle="yes">ALK</italic>+ unresectable advanced or recurrent NSCLC.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref><sup>,</sup><xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> On November 25, 2021, lorlatinib approval was expanded to include 1L treatment in patients with <italic toggle="yes">ALK</italic>+ advanced NSCLC.<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref><sup>,</sup><xref rid="bib8" ref-type="bibr"><sup>8</sup></xref> Lorlatinib inhibits tumors that express <italic toggle="yes">ALK</italic> resistance mutations, including G1202R, that develop after treatment with first- and second-generation ALK inhibitors such as crizotinib and alectinib, respectively.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="bib5" ref-type="bibr"><sup>5</sup></xref><sup>,</sup><xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> One report suggests that 45% to 70% of treatment failure on ALK TKIs is due to brain metastases, making this the most common failure site.<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> Lorlatinib is designed to cross the blood-brain barrier and penetrate the central nervous system (CNS) to target these brain metastases.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref><sup>,</sup><xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> There is evidence that reveals that lorlatinib has an impact on brain metastases, and there are favorable efficacy data in previous clinical trials.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="bib12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="bib13" ref-type="bibr"><sup>13</sup></xref></p><p id="p0020">In a phase 1 trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01970865">NCT01970865</ext-link>), lorlatinib was found to have both systemic and intracranial efficacies in patients with <italic toggle="yes">ALK</italic>+ advanced NSCLC, including those with brain metastases and those who previously failed TKIs.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="bib14" ref-type="bibr"><sup>14</sup></xref> A subsequent post hoc analysis of this study was performed to find the safety, efficacy, and pharmacokinetics of lorlatinib in the Japanese subgroup population. In this subgroup analysis, lorlatinib had a clinically meaningful overall response and intracranial response in Japanese patients with <italic toggle="yes">ALK</italic>+ NSCLC after prior ALK TKI use in this trial.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> In a retrospective study, lorlatinib was found to be efficacious after failure of alectinib in patients with <italic toggle="yes">ALK</italic>+ NSCLC.<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> To date, this was the only evidence in actual clinical practice of lorlatinib after 1L alectinib in Japan; however, this was at a single institution.</p><p id="p0025">Although lorlatinib was found to have efficacy for the second-line (2L) treatment of <italic toggle="yes">ALK</italic>+ NSCLC within these trials, there have been a limited number of reports on evidence about the efficacy of lorlatinib after 1L alectinib in actual clinical practice in Japan. We conducted a real-world observational study to record characteristics of patients treated with lorlatinib, collect information on utilization of lorlatinib, and determine its clinical efficacy in patients with <italic toggle="yes">ALK</italic>+ NSCLC.</p></sec><sec id="sec2"><title>Materials and Methods</title><sec id="sec2.1"><title>Study Design and Patients</title><p id="p0030">This multicenter, retrospective, observational study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04979988">NCT04979988</ext-link>) was conducted at 16 sites in Japan and included patients who had been treated with lorlatinib in any line after 1L alectinib. Eligible patients had any-stage <italic toggle="yes">ALK</italic>+ NSCLC, confirmed treatment with alectinib in the 1L setting, availability of clinical information from medical records, and started lorlatinib between May 1, 2019, and December 31, 2020. To avoid the timing of inclusion bias as much as possible, real-world clinical evaluations were conducted on patients who started treatment (6 mo after launch in November 2018 in Japan). To obtain a sufficient observation period with reference to the clinical study results (median progression-free survival), patients who had been on treatment for more than or equal to 6 months were included in the study.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> This study excluded patients participating in any clinical trials of which final results had not yet been reported during the study period. All patients provided written or verbal informed consent before the initiation of the study.</p></sec><sec id="sec2.2"><title>Study End Points</title><p id="p0035">Primary objectives were to collect patient demographics at baseline (date at which patients started alectinib) and estimate time to treatment failure (TTF) in patients treated with lorlatinib in the 2L or third or later line (&#8805;3L). TTF of lorlatinib was defined as the time from the date of first treatment administration of lorlatinib to the date of treatment discontinuation of lorlatinib owing to any cause, including disease progression, treatment toxicity, or death. Secondary end points included objective response rate (ORR) with lorlatinib beyond the 2L or &#8805;3L, reason for discontinuation of each line of therapy, TTF of alectinib and subsequent therapies used, ORR with alectinib, time to last treatment failure (TLTF), and combined TTF. ORR was defined as complete or partial response in a method that complies with Response Evaluation Criteria in Solid Tumors version 1.1 tumor assessment as closely as possible in clinical practice, according to the investigator&#8217;s assessment. TLTF was defined as the time from the first date of alectinib treatment to the date of any last treatment discontinuation from any cause, including disease progression, treatment toxicity, or death during the last treatment. Combined TTF was defined as the sum of TTF of alectinib and subsequent therapy, including lorlatinib. Adverse event (AE) data were not collected except as reasons for discontinuation.</p></sec><sec id="sec2.3"><title>Statistics</title><p id="p0040">Patient demographics at baseline were summarized using descriptive analyses. Median TTF was estimated using the Kaplan-Meier method. Percentiles of survival curves (25%, median, and 75%) with their two-sided 95% confidence intervals (CIs) were estimated. ORR was estimated using the number of patients with a best overall response divided by the patients in the full analysis set, which includes patients who met&#160;all the inclusion criteria and no exclusion criteria. Exploratory analyses were conducted using the Cox proportional hazards model to identify covariate factors affecting TTF and the effect of lorlatinib on the incidence of brain metastases in patients with or without brain metastases at lorlatinib initiation.</p></sec></sec><sec id="sec3"><title>Results</title><sec id="sec3.1"><title>Patients</title><p id="p0045">Of the 51 patients included in the study, 29 (56.9%) received 2L lorlatinib, and 22 (43.1%) received &#8805;3L lorlatinib treatment. Overall, 25 patients (49.0%) reported to have never smoked at the start of alectinib treatment (<xref rid="appsec1" ref-type="sec">Supplementary Table&#160;1</xref>). The median age at the start of lorlatinib treatment was 59 years (range: 33&#8211;79 y) in any line, 57 years (range: 36&#8211;76 y) in 2L, and 63 years (range: 33&#8211;79 y) in &#8805;3L. Most patients were below 65 years of age (34 patients [66.7%] in any line, 20 [69.0%] in 2L, 14 [63.6%] in &#8805;3L). All patients had metastases before lorlatinib treatment, with some having multiple locations of metastatic lesions. The most common site for metastatic lesions was lymph node affiliation (41 patients [80.4%] in any line). Brain metastases at the start of lorlatinib treatment were reported in 25 patients (49.0%) with any line of treatment. In patients receiving 2L lorlatinib treatment, 19 (65.5%) had an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1, four (13.8%) had an ECOG PS of greater than or equal to 2, and six (20.7%) had an unknown ECOG PS. In patients receiving &#8805;3L lorlatinib treatment, 13 (59.1%) had an ECOG PS of 0 or 1, four (18.2%) had an ECOG PS of &#8805;2, and five (22.7%) had an unknown ECOG PS (<xref rid="tbl1" ref-type="table">Table&#160;1</xref>). The subsequent treatment patterns after alectinib, including lorlatinib up to 3L, were as follows: alectinib followed by lorlatinib and then chemotherapy (n&#160;= 11); alectinib followed by lorlatinib and then another ALK TKI (n&#160;= 4); and alectinib followed by chemotherapy or an ALK TKI and then lorlatinib (n&#160;= 15). ORR with alectinib was 80.0% (95% CI: 65.4%&#8211;90.4%) (<xref rid="appsec1" ref-type="sec">Supplementary Table&#160;2</xref>). Median TTF of 1L alectinib was 18.1 months (95% CI: 10.5&#8211;24.2 mo) (<xref rid="appsec1" ref-type="sec">Supplementary Fig.&#160;1</xref>). Data cutoff was October 15,&#160;2021.<table-wrap position="float" id="tbl1" orientation="portrait"><label>Table&#160;1</label><caption><p>Baseline Patient Characteristics by Lorlatinib Line of Therapy</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Characteristics</th><th colspan="1" rowspan="1">Any Line<break/>N&#160;= 51</th><th colspan="1" rowspan="1">2L n&#160;= 29</th><th colspan="1" rowspan="1">&#8805;3L n&#160;= 22</th></tr></thead><tbody><tr><td colspan="4" rowspan="1">Start of lorlatinib treatment</td></tr><tr><td colspan="1" rowspan="1">Age, median (range), y</td><td colspan="1" rowspan="1">59 (33&#8211;79)</td><td colspan="1" rowspan="1">57 (36&#8211;76)</td><td colspan="1" rowspan="1">63 (33&#8211;79)</td></tr><tr><td colspan="1" rowspan="1">&#160;&lt;65 y, n (%)</td><td colspan="1" rowspan="1">29 (56.9)</td><td colspan="1" rowspan="1">18 (62.1)</td><td colspan="1" rowspan="1">11 (50.0)</td></tr><tr><td colspan="1" rowspan="1">&#160;&#8805;65 y, n (%)</td><td colspan="1" rowspan="1">22 (43.1)</td><td colspan="1" rowspan="1">11 (37.9)</td><td colspan="1" rowspan="1">11 (50.0)</td></tr><tr><td colspan="1" rowspan="1">Presence of metastases, n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Yes</td><td colspan="1" rowspan="1">51 (100)</td><td colspan="1" rowspan="1">29 (100)</td><td colspan="1" rowspan="1">22 (100)</td></tr><tr><td colspan="1" rowspan="1">Metastatic lesion, n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Lymph node affiliation</td><td colspan="1" rowspan="1">41 (80.4)</td><td colspan="1" rowspan="1">23 (79.3)</td><td colspan="1" rowspan="1">18 (81.8)</td></tr><tr><td colspan="1" rowspan="1">&#160;Bone</td><td colspan="1" rowspan="1">31 (60.8)</td><td colspan="1" rowspan="1">17 (58.6)</td><td colspan="1" rowspan="1">14 (63.6)</td></tr><tr><td colspan="1" rowspan="1">&#160;Brain</td><td colspan="1" rowspan="1">25 (49.0)</td><td colspan="1" rowspan="1">13 (44.8)</td><td colspan="1" rowspan="1">12 (54.5)</td></tr><tr><td colspan="1" rowspan="1">&#160;Ipsilateral lung</td><td colspan="1" rowspan="1">18 (35.3)</td><td colspan="1" rowspan="1">11 (37.9)</td><td colspan="1" rowspan="1">7 (31.8)</td></tr><tr><td colspan="1" rowspan="1">&#160;Contralateral lung</td><td colspan="1" rowspan="1">12 (23.5)</td><td colspan="1" rowspan="1">7 (24.1)</td><td colspan="1" rowspan="1">5 (22.7)</td></tr><tr><td colspan="1" rowspan="1">&#160;Liver</td><td colspan="1" rowspan="1">11 (21.6)</td><td colspan="1" rowspan="1">7 (24.1)</td><td colspan="1" rowspan="1">4 (18.2)</td></tr><tr><td colspan="1" rowspan="1">&#160;Remote lymph node</td><td colspan="1" rowspan="1">11 (21.6)</td><td colspan="1" rowspan="1">5 (17.2)</td><td colspan="1" rowspan="1">6 (27.3)</td></tr><tr><td colspan="1" rowspan="1">&#160;Adrenal glands</td><td colspan="1" rowspan="1">3 (5.9)</td><td colspan="1" rowspan="1">1 (3.4)</td><td colspan="1" rowspan="1">2 (9.1)</td></tr><tr><td colspan="1" rowspan="1">&#160;Kidney</td><td colspan="1" rowspan="1">1 (2.0)</td><td colspan="1" rowspan="1">1 (3.4)</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">&#160;Other</td><td colspan="1" rowspan="1">16 (31.4)</td><td colspan="1" rowspan="1">11 (37.9)</td><td colspan="1" rowspan="1">5 (22.7)</td></tr><tr><td colspan="1" rowspan="1">Line of treatment, n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;2L</td><td colspan="1" rowspan="1">29 (56.9)</td><td colspan="1" rowspan="1">29 (100.0)</td><td colspan="1" rowspan="1">0 (0.0)</td></tr><tr><td colspan="1" rowspan="1">&#160;3L</td><td colspan="1" rowspan="1">15 (29.4)</td><td colspan="1" rowspan="1">0 (0.0)</td><td colspan="1" rowspan="1">15 (68.2)</td></tr><tr><td colspan="1" rowspan="1">&#160;4L</td><td colspan="1" rowspan="1">1 (2.0)</td><td colspan="1" rowspan="1">0 (0.0)</td><td colspan="1" rowspan="1">1 (4.5)</td></tr><tr><td colspan="1" rowspan="1">&#160;5L</td><td colspan="1" rowspan="1">4 (7.8)</td><td colspan="1" rowspan="1">0 (0.0)</td><td colspan="1" rowspan="1">4 (18.2)</td></tr><tr><td colspan="1" rowspan="1">&#160;6L</td><td colspan="1" rowspan="1">1 (2.0)</td><td colspan="1" rowspan="1">0 (0.0)</td><td colspan="1" rowspan="1">1 (4.5)</td></tr><tr><td colspan="1" rowspan="1">&#160;7L</td><td colspan="1" rowspan="1">1 (2.0)</td><td colspan="1" rowspan="1">0 (0.0)</td><td colspan="1" rowspan="1">1 (4.5)</td></tr><tr><td colspan="1" rowspan="1">ECOG PS, n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;0</td><td colspan="1" rowspan="1">7 (13.7)</td><td colspan="1" rowspan="1">5 (17.2)</td><td colspan="1" rowspan="1">2 (9.1)</td></tr><tr><td colspan="1" rowspan="1">&#160;1</td><td colspan="1" rowspan="1">25 (49.0)</td><td colspan="1" rowspan="1">14 (48.3)</td><td colspan="1" rowspan="1">11 (50.0)</td></tr><tr><td colspan="1" rowspan="1">&#160;2</td><td colspan="1" rowspan="1">5 (9.8)</td><td colspan="1" rowspan="1">3 (10.3)</td><td colspan="1" rowspan="1">2 (9.1)</td></tr><tr><td colspan="1" rowspan="1">&#160;3</td><td colspan="1" rowspan="1">3 (5.9)</td><td colspan="1" rowspan="1">1 (3.4)</td><td colspan="1" rowspan="1">2 (9.1)</td></tr><tr><td colspan="1" rowspan="1">&#160;Unknown</td><td colspan="1" rowspan="1">11 (21.6)</td><td colspan="1" rowspan="1">6 (20.7)</td><td colspan="1" rowspan="1">5 (22.7)</td></tr><tr><td colspan="1" rowspan="1">End of lorlatinib treatment</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Presence of metastases, n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Yes</td><td colspan="1" rowspan="1">47 (92.2)</td><td colspan="1" rowspan="1">28 (96.6)</td><td colspan="1" rowspan="1">19 (86.4)</td></tr><tr><td colspan="1" rowspan="1">&#160;Unknown or unconfirmed</td><td colspan="1" rowspan="1">4 (7.8)</td><td colspan="1" rowspan="1">1 (3.4)</td><td colspan="1" rowspan="1">3 (13.6)</td></tr><tr><td colspan="1" rowspan="1">Metastatic lesion, n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Lymph node affiliation</td><td colspan="1" rowspan="1">38 (80.9)</td><td colspan="1" rowspan="1">21 (75.0)</td><td colspan="1" rowspan="1">17 (89.5)</td></tr><tr><td colspan="1" rowspan="1">&#160;Bone</td><td colspan="1" rowspan="1">29 (61.7)</td><td colspan="1" rowspan="1">15 (53.6)</td><td colspan="1" rowspan="1">14 (73.7)</td></tr><tr><td colspan="1" rowspan="1">&#160;Brain</td><td colspan="1" rowspan="1">23 (48.9)</td><td colspan="1" rowspan="1">13 (46.4)</td><td colspan="1" rowspan="1">10 (52.6)</td></tr><tr><td colspan="1" rowspan="1">&#160;Ipsilateral lung</td><td colspan="1" rowspan="1">16 (34.0)</td><td colspan="1" rowspan="1">9 (32.1)</td><td colspan="1" rowspan="1">7 (36.8)</td></tr><tr><td colspan="1" rowspan="1">&#160;Remote lymph node</td><td colspan="1" rowspan="1">14 (29.8)</td><td colspan="1" rowspan="1">7 (25.0)</td><td colspan="1" rowspan="1">7 (36.8)</td></tr><tr><td colspan="1" rowspan="1">&#160;Liver</td><td colspan="1" rowspan="1">12 (25.5)</td><td colspan="1" rowspan="1">7 (25.0)</td><td colspan="1" rowspan="1">5 (26.3)</td></tr><tr><td colspan="1" rowspan="1">&#160;Contralateral lung</td><td colspan="1" rowspan="1">10 (21.3)</td><td colspan="1" rowspan="1">5 (17.9)</td><td colspan="1" rowspan="1">5 (26.3)</td></tr><tr><td colspan="1" rowspan="1">&#160;Adrenal glands</td><td colspan="1" rowspan="1">3 (6.4)</td><td colspan="1" rowspan="1">1 (3.6)</td><td colspan="1" rowspan="1">2 (10.5)</td></tr><tr><td colspan="1" rowspan="1">&#160;Kidney</td><td colspan="1" rowspan="1">1 (2.1)</td><td colspan="1" rowspan="1">1 (3.6)</td><td colspan="1" rowspan="1">0 (0.0)</td></tr><tr><td colspan="1" rowspan="1">&#160;Other</td><td colspan="1" rowspan="1">18 (35.3)</td><td colspan="1" rowspan="1">12 (41.4)</td><td colspan="1" rowspan="1">6 (27.3)</td></tr><tr><td colspan="1" rowspan="1">ECOG PS, n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;0</td><td colspan="1" rowspan="1">11 (21.6)</td><td colspan="1" rowspan="1">6 (20.7)</td><td colspan="1" rowspan="1">5 (22.7)</td></tr><tr><td colspan="1" rowspan="1">&#160;1</td><td colspan="1" rowspan="1">19 (37.3)</td><td colspan="1" rowspan="1">14 (48.3)</td><td colspan="1" rowspan="1">5 (22.7)</td></tr><tr><td colspan="1" rowspan="1">&#160;2</td><td colspan="1" rowspan="1">3 (5.9)</td><td colspan="1" rowspan="1">1 (3.4)</td><td colspan="1" rowspan="1">2 (9.1)</td></tr><tr><td colspan="1" rowspan="1">&#160;3</td><td colspan="1" rowspan="1">2 (3.9)</td><td colspan="1" rowspan="1">1 (3.4)</td><td colspan="1" rowspan="1">1 (4.5)</td></tr><tr><td colspan="1" rowspan="1">&#160;4</td><td colspan="1" rowspan="1">4 (7.8)</td><td colspan="1" rowspan="1">2 (6.9)</td><td colspan="1" rowspan="1">2 (9.1)</td></tr><tr><td colspan="1" rowspan="1">&#160;Unknown</td><td colspan="1" rowspan="1">12 (23.5)</td><td colspan="1" rowspan="1">5 (17.2)</td><td colspan="1" rowspan="1">7 (31.8)</td></tr><tr><td colspan="1" rowspan="1">Reason for discontinuation of lorlatinib, n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Progression</td><td colspan="1" rowspan="1">25 (49.0)</td><td colspan="1" rowspan="1">16 (55.2)</td><td colspan="1" rowspan="1">9 (40.9)</td></tr><tr><td colspan="1" rowspan="1">&#160;AE</td><td colspan="1" rowspan="1">7 (13.7)</td><td colspan="1" rowspan="1">3 (10.3)</td><td colspan="1" rowspan="1">4 (18.2)</td></tr><tr><td colspan="1" rowspan="1">&#160;Other</td><td colspan="1" rowspan="1">2 (3.9)</td><td colspan="1" rowspan="1">1 (3.4)</td><td colspan="1" rowspan="1">1 (4.5)</td></tr></tbody></table><table-wrap-foot><fn><p>2L, second line; 3L, third line; 4L, fourth line; 5L, fifth line; 6L, sixth line; 7L, seventh line; AE, adverse event; ECOG PS, Eastern Cooperative Oncology Group performance status.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec3.2"><title>Time to Treatment Failure</title><p id="p0050">Median TTF was 11.1 months (95% CI: 4.6&#8211;13.8 mo) in patients with any line of lorlatinib treatment (<xref rid="fig1" ref-type="fig">Fig.&#160;1</xref><italic toggle="yes">A</italic>), 10.8 months (95% CI: 3.9&#8211;13.8 mo) with 2L lorlatinib (<xref rid="fig1" ref-type="fig">Fig.&#160;1</xref><italic toggle="yes">B</italic>), and 11.5 months (95% CI: 2.9 mo&#8211;not reached [NR]) with &#8805;3L lorlatinib (<xref rid="fig1" ref-type="fig">Fig.&#160;1</xref><italic toggle="yes">C</italic>). Median TTF was 11.5 months (95% CI: 3.9 mo&#8211;NR) in patients with brain metastases at lorlatinib initiation and 9.9 months (95%&#160;CI: 4.3&#8211;13.8 mo) in patients without brain metastases (<xref rid="fig2" ref-type="fig">Fig.&#160;2</xref>). Cox proportional hazards model showed that the presence of brain metastases at lorlatinib initiation did not affect TTF (Supplementary Fig. 2A and B).<fig id="fig1" position="float" orientation="portrait"><label>Figure&#160;1</label><caption><p>TTF of lorlatinib with (<italic toggle="yes">A</italic>) any line, (<italic toggle="yes">B</italic>) 2L, and (<italic toggle="yes">C</italic>) &#8805;3L. 2L, second line; 3L, third line; NR, not reached; TTF, time to treatment failure.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig><fig id="fig2" position="float" orientation="portrait"><label>Figure&#160;2</label><caption><p>TTF with and without brain metastasis, lorlatinib any line. NR, not reached; TTF, time to treatment failure.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p><p id="p0055">Median TLTF was 59.7 months (95% CI: 39.5 mo&#8211;NR) in patients with any-line lorlatinib treatment (<xref rid="fig3" ref-type="fig">Fig.&#160;3</xref><italic toggle="yes">A</italic>), not reached (95% CI: 32.2 mo&#8211;NR) with 2L lorlatinib (<xref rid="fig3" ref-type="fig">Fig.&#160;3</xref><italic toggle="yes">B</italic>), and 59.7 months (95% CI: 35.5 mo&#8211;NR) with &#8805;3L lorlatinib (<xref rid="fig3" ref-type="fig">Fig.&#160;3</xref><italic toggle="yes">C</italic>). With 1L alectinib treatment, median TLTF was 76.9 months (95% CI, 39.4 months-NR) in patients with baseline brain metastases and 59.7 months (95% CI, 34.3 months-NR) in patients without baseline brain metastases (Supplementary Fig. 3). Combined TTF was not reached (95% CI: 27.2 mo&#8211;NR) with 2L lorlatinib treatment (<xref rid="appsec1" ref-type="sec">Supplementary Fig.&#160;4A</xref>) and 55.0 months (95% CI: 34.9 mo&#8211;NR) for &#8805;3L lorlatinib treatment (<xref rid="appsec1" ref-type="sec">Supplementary Fig.&#160;4B</xref>). Median TTF was 5.5 months (95% CI, 1.2-11.4) in patients who had TTF of &lt;18.1 months and 13.1 months (95% CI, 3.8-NR) in patients who had TTF of &#8805;18.1 months with 1L alectinib (Supplementary Fig. 5A and B).<fig id="fig3" position="float" orientation="portrait"><label>Figure&#160;3</label><caption><p>TLTF of lorlatinib with (<italic toggle="yes">A</italic>) any line, (<italic toggle="yes">B</italic>) 2L, and (<italic toggle="yes">C</italic>) &#8805;3L. 2L, second line; 3L, third line; NR, not reached; TLTF, time to last treatment failure.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig></p></sec><sec id="sec3.3"><title>Treatment Response Summary and Reason for Discontinuation</title><p id="p0060">ORR was 35.7% with any-line lorlatinib, 44.0% with 2L, and 23.5% with &#8805;3L. Complete response was achieved in two patients (4.8%) treated with any-line lorlatinib, two (8.0%) with 2L, and zero with &#8805;3L. Partial response was achieved in 13 patients (31.0%) treated with any-line lorlatinib, nine (36%) with 2L, and four (23.5%) with &#8805;3L. Stable disease occurred in 11 patients (26.2%) treated with any-line lorlatinib, six (24.0%) with 2L, and five (29.4%) with &#8805;3L (<xref rid="tbl2" ref-type="table">Table&#160;2</xref>). Patients discontinued any line of lorlatinib treatment owing to disease progression (n&#160;= 25, 49.0%), AEs (n&#160;= 7, 13.7%), or other causes (n&#160;= 2, 3.9%) (<xref rid="appsec1" ref-type="sec">Supplementary Fig.&#160;6</xref>).<table-wrap position="float" id="tbl2" orientation="portrait"><label>Table&#160;2</label><caption><p>Response Summary in Patients Who Were Evaluated on Lorlatinib Treatment</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Patients</th><th colspan="1" rowspan="1">Any Line</th><th colspan="1" rowspan="1">2L</th><th colspan="1" rowspan="1">&#8805;3L</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">All patients, n<xref rid="tbl2fna" ref-type="table-fn">a</xref></td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">25</td><td colspan="1" rowspan="1">17</td></tr><tr><td colspan="1" rowspan="1">Results of evaluation of treatment effect, n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;CR</td><td colspan="1" rowspan="1">2 (4.8)</td><td colspan="1" rowspan="1">2 (8.0)</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">&#160;PR</td><td colspan="1" rowspan="1">13 (31.0)</td><td colspan="1" rowspan="1">9 (36.0)</td><td colspan="1" rowspan="1">4 (23.5)</td></tr><tr><td colspan="1" rowspan="1">&#160;SD</td><td colspan="1" rowspan="1">11 (26.2)</td><td colspan="1" rowspan="1">6 (24.0)</td><td colspan="1" rowspan="1">5 (29.4)</td></tr><tr><td colspan="1" rowspan="1">&#160;Non-CR or non-PD</td><td colspan="1" rowspan="1">3 (7.1)</td><td colspan="1" rowspan="1">1 (4.0)</td><td colspan="1" rowspan="1">2 (11.8)</td></tr><tr><td colspan="1" rowspan="1">&#160;PD</td><td colspan="1" rowspan="1">13 (31.0)</td><td colspan="1" rowspan="1">7 (28.0)</td><td colspan="1" rowspan="1">6 (35.3)</td></tr><tr><td colspan="1" rowspan="1">ORR (95% CI), %</td><td colspan="1" rowspan="1">35.7</td><td colspan="1" rowspan="1">44.0</td><td colspan="1" rowspan="1">23.5</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">(21.6&#8211;52.0)</td><td colspan="1" rowspan="1">(24.4&#8211;65.1)</td><td colspan="1" rowspan="1">(6.8&#8211;49.9)</td></tr><tr><td colspan="1" rowspan="1">Patients with brain metastases, n</td><td colspan="1" rowspan="1">21</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">10</td></tr><tr><td colspan="1" rowspan="1">Results of evaluation of treatment effect, n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;PR</td><td colspan="1" rowspan="1">6 (28.6)</td><td colspan="1" rowspan="1">4 (36.4)</td><td colspan="1" rowspan="1">2 (20.0)</td></tr><tr><td colspan="1" rowspan="1">&#160;SD</td><td colspan="1" rowspan="1">7 (33.3)</td><td colspan="1" rowspan="1">3 (27.3)</td><td colspan="1" rowspan="1">4 (40.0)</td></tr><tr><td colspan="1" rowspan="1">&#160;Non-CR/non-PD</td><td colspan="1" rowspan="1">2 (9.5)</td><td colspan="1" rowspan="1">0 (0.0)</td><td colspan="1" rowspan="1">2 (20.0)</td></tr><tr><td colspan="1" rowspan="1">&#160;PD</td><td colspan="1" rowspan="1">6 (28.6)</td><td colspan="1" rowspan="1">4 (36.4)</td><td colspan="1" rowspan="1">2 (20.0)</td></tr><tr><td colspan="1" rowspan="1">ORR (95% CI), %</td><td colspan="1" rowspan="1">28.6</td><td colspan="1" rowspan="1">36.4</td><td colspan="1" rowspan="1">20.0</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">(11.3&#8211;52.2)</td><td colspan="1" rowspan="1">(10.9&#8211;69.2)</td><td colspan="1" rowspan="1">(2.5&#8211;55.6)</td></tr><tr><td colspan="1" rowspan="1">Patients without brain metastases, n</td><td colspan="1" rowspan="1">21</td><td colspan="1" rowspan="1">14</td><td colspan="1" rowspan="1">7</td></tr><tr><td colspan="1" rowspan="1">Results of evaluation of treatment effect, n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;CR</td><td colspan="1" rowspan="1">2 (9.5)</td><td colspan="1" rowspan="1">2 (14.3)</td><td colspan="1" rowspan="1">0 (0.0)</td></tr><tr><td colspan="1" rowspan="1">&#160;PR</td><td colspan="1" rowspan="1">7 (33.3)</td><td colspan="1" rowspan="1">5 (35.7)</td><td colspan="1" rowspan="1">2 (28.6)</td></tr><tr><td colspan="1" rowspan="1">&#160;SD</td><td colspan="1" rowspan="1">4 (19.0)</td><td colspan="1" rowspan="1">3 (21.4)</td><td colspan="1" rowspan="1">1 (14.3)</td></tr><tr><td colspan="1" rowspan="1">&#160;Non-CR/non-PD</td><td colspan="1" rowspan="1">1 (4.8)</td><td colspan="1" rowspan="1">1 (7.1)</td><td colspan="1" rowspan="1">0 (0.0)</td></tr><tr><td colspan="1" rowspan="1">&#160;PD</td><td colspan="1" rowspan="1">7 (33.3)</td><td colspan="1" rowspan="1">3 (21.4)</td><td colspan="1" rowspan="1">4 (57.1)</td></tr><tr><td colspan="1" rowspan="1">ORR (95% CI), %</td><td colspan="1" rowspan="1">42.9</td><td colspan="1" rowspan="1">50.0</td><td colspan="1" rowspan="1">28.6</td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">(21.8&#8211;66.0)</td><td colspan="1" rowspan="1">(23.0&#8211;77.0)</td><td colspan="1" rowspan="1">(3.7&#8211;71.0)</td></tr></tbody></table><table-wrap-foot><fn><p>2L, second line; 3L, third line; CR, complete response; ORR, objective response rate; PD, progressive disease; PR, partial response; SD, stable disease.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fna"><label>a</label><p id="ntpara0020">Number of cases with confirmed tumor evaluation in the medical records.</p></fn></table-wrap-foot></table-wrap></p><p id="p0065">At the start of lorlatinib treatment, 25 patients (49.0%) had brain metastases, and 26 (51.0%) had no brain metastases. Of the 26 patients without brain metastases, 19 had discontinued lorlatinib at data cutoff. Of these 19 patients, three discontinuations were due to AEs, 15 were due to disease progression, and one was due to other causes. There was no incidence of new brain metastases at the time of lorlatinib discontinuation (<xref rid="fig4" ref-type="fig">Fig.&#160;4</xref>).<fig id="fig4" position="float" orientation="portrait"><label>Figure&#160;4</label><caption><p>Cases with or without BM at start of lorlatinib and at data cutoff. AE, adverse event; BM, brain metastasis; CNS, central nervous system.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr4.jpg"/></fig></p></sec></sec><sec id="sec4"><title>Discussion</title><p id="p0070">In this observational study, we found the efficacy of lorlatinib to be comparable with previous reports of lorlatinib given after 1L alectinib in patients with <italic toggle="yes">ALK</italic>+ NSCLC in clinical practice in Japan and globally.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> The efficacy observed in patients treated with lorlatinib with or without brain metastases at lorlatinib initiation was similar to previous reports,<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> and no new brain metastases were reported throughout treatment in this follow-up period.</p><p id="p0075">The efficacy of 1L alectinib in this patient group had a median TTF of 18.1 months (95% CI: 10.5&#8211;24.2 mo) and an ORR of 80.0% (95% CI: 65.4%&#8211;90.4%). Although the patient population selected in this study had treatment failure with 1L alectinib, the efficacy of alectinib was comparable with results found in previous reports.<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> At lorlatinib initiation, brain metastases were present in 49.0% of patients with any-line treatment, which was slightly lower than the previous single-institution study.<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> The current study included 49.0% of patients who had never smoked, which is similar to the previous report with 56% of patients being never smokers in the lorlatinib group.<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> A higher proportion (16.0%) of patients in the current study had an ECOG PS greater than or equal to 2 compared with none in the phase 2 study, which was a major difference and gives this study more generalizability to a larger patient population and increases its validity.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> The only difference in patient characteristics between 2L and &#8805;3L was an inversion of the male to female ratio. Although the possibility cannot be ruled out that the study may be affected by selection bias&#160;(in terms of inclusion criteria, timing of implementation, etc.), the reason for this is unknown. Other patient characteristics are comparable with previous reports.<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="bib17" ref-type="bibr"><sup>17</sup></xref></p><p id="p0080">The median TTF was more than 10 months when lorlatinib was given after alectinib in Japanese patients with <italic toggle="yes">ALK</italic>+ NSCLC. Median TTFs of lorlatinib for any line, 2L, and &#8805;3L were comparable with the results of previous clinical studies and real-world data.<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref><sup>,</sup><xref rid="bib17" ref-type="bibr"><sup>17</sup></xref> The ORR was higher in patients with 2L lorlatinib treatment compared with &#8805;3L lorlatinib; however, lorlatinib had efficacy when used in both settings. Although the ORR in this study was assessed in a real-world setting, it was considered comparable with other clinical studies and reports.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref><sup>,</sup><xref rid="bib13" ref-type="bibr"><sup>13</sup></xref><sup>,</sup><xref rid="bib16" ref-type="bibr">16</xref>, <xref rid="bib17" ref-type="bibr">17</xref>, <xref rid="bib18" ref-type="bibr">18</xref>, <xref rid="bib19" ref-type="bibr">19</xref></p><p id="p0085">The efficacy data presented in this study were comparable with those in previously published clinical trials and reports.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="bib5" ref-type="bibr"><sup>5</sup></xref><sup>,</sup><xref rid="bib17" ref-type="bibr"><sup>17</sup></xref><sup>,</sup><xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> A certain duration of lorlatinib treatment was ensured for patients with or without brain metastases. The end points of this study did not include a comparison of TTF between lorlatinib after 1L alectinib and chemotherapy after 1L alectinib owing to the small sample size. Although this study did not compare the clinical benefit between lorlatinib and chemotherapy in the &#8805;2L setting, in a recent real-world study, the clinical benefit was similar between &#8805;2L chemotherapy and lorlatinib.<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> Nevertheless, these results were considered inconclusive because the analysis did not account for variability in patient characteristics. Another study that adjusted for patient characteristics by using matching-adjusted indirect comparison revealed that the clinical benefit with lorlatinib was better than chemotherapy as &#8805;2L therapy when used in the TKI-TKI sequence.<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref> On the basis of the results from these previous studies, lorlatinib may be a promising option after alectinib; however, further investigation is warranted.<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref><sup>,</sup><xref rid="bib20" ref-type="bibr"><sup>20</sup></xref></p><p id="p0090">No new brain metastases were reported in the 19 patients who did not have brain metastases at the time of lorlatinib initiation and completion of treatment at the data cutoff. This might be expected, as lorlatinib has intracranial activity and is likely to be effective in reducing the development of new brain metastases after 1L alectinib in the real-world clinical setting.<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref><sup>,</sup><xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> In a previous report with lorlatinib after alectinib, patients without CNS metastases at baseline had a lower cumulative incidence rate of CNS progression over time.<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref></p><p id="p0095">Median TTF was shorter for patients who discontinued owing to AEs than those who discontinued owing to disease progression. In a previous study, the&#160;incidence of discontinuation owing to treatment-related AEs was low (3%) with lorlatinib, and no treatment-related deaths were reported.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> Therefore, it is important to manage AEs so that patients can continue lorlatinib treatment for as long as needed.</p><p id="p0100">Overall survival could not be evaluated in this study; therefore, TLTF was considered an alternative outcome. Given that the median TLTF was 59.7 months, lorlatinib treatment in the &#8805;2L setting in the real world was expected to have a long-term prognosis of approximately 5 years. The previous real-world study revealed no significant difference between chemotherapy and lorlatinib as 2L therapy in terms of overall survival.<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> Nevertheless, our data suggest that lorlatinib 2L therapy in long-term follow-up, in terms of TLTF or combined TTF, provides a potential benefit for patients. Because there was almost no discrepancy between combined TTF and TLTF for both 2L and &#8805;3L lorlatinib treatment, TLTF data in this study were less affected by drug withdrawal and other factors. Lorlatinib treatment had benefit in all patients regardless of the presence or absence of brain metastases at the time of initial diagnosis. Although biomarker information was not collected in this study, resistance mutations developed on alectinib treatment have been found to preclude patients from responding to ALK TKIs.<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref><sup>,</sup><xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> It is noteworthy that these patients, who would have been otherwise difficult to treat, responded to lorlatinib.</p><p id="p0105">To our knowledge, this is the first multicenter, real-world study in Japan that collected data on patients who received lorlatinib treatment after 1L alectinib treatment. Nevertheless, there were several limitations to our study. First, this was a small retrospective study in which only patients who received and completed 1L alectinib treatment were selected contributing to the small population size. This study, however, included all lines of lorlatinib treatment after 1L alectinib. Second, information on the presence or absence of brain metastases was collected according to the judgment of the primary investigators owing to this being a retrospective study. Third, this study did not evaluate the effects of radiotherapy on brain metastases, disease progression owing to brain metastases, details of AEs, or overall survival. Finally, the duration of lorlatinib dosing initiation was limited. Future real-world studies reporting results from 1L lorlatinib use and pragmatic sequences of post-lorlatinib therapy to evaluate outcomes in patients exposed to 1L lorlatinib would be valuable.</p><p id="p0110">In this multicenter, retrospective study, patient characteristics were almost comparable with previous reports in patients with advanced <italic toggle="yes">ALK</italic>+ NSCLC who had previously been treated with 1L alectinib. The slight differences could be attributed to clinical characteristics of the patient population, such as difference in the proportion of patients with an ECOG PS greater than or equal to 2. Median TTF of lorlatinib was comparable for patients with or without brain metastases at lorlatinib initiation. No new brain metastases were reported throughout treatment in this follow-up period. The results of this study provided evidence of the benefit with lorlatinib as 2L or later-line treatment after failure with alectinib, which was consistent with efficacy of lorlatinib in the phase 2 study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01970865">NCT01970865</ext-link>).</p></sec><sec id="sec5"><title>CRediT Authorship Contribution Statement</title><p id="p0115"><bold>Yasushi Goto:</bold> Investigation, Writing&#8212;review and editing.</p><p id="p0120"><bold>Hirotsugu Kenmotsu:</bold> Investigation, Writing&#8212;review and editing.</p><p id="p0125"><bold>Motohiro Tamiya:</bold> Investigation, Writing&#8212;review and editing.</p><p id="p0130"><bold>Shuji Murakami:</bold> Investigation, Writing&#8212;review and editing.</p><p id="p0135"><bold>Takayasu Kurata:</bold> Investigation, Writing&#8212;review and editing.</p><p id="p0140"><bold>Noriko Yanagitani:</bold> Investigation, Writing&#8212;review and editing.</p><p id="p0145"><bold>Hirokazu Taniguchi:</bold> Investigation, Writing&#8212;review and editing.</p><p id="p0150"><bold>Shoichi Kuyama:</bold> Investigation, Writing&#8212;review and editing.</p><p id="p0155"><bold>Junichi Shimizu:</bold> Investigation, Writing&#8212;review and editing.</p><p id="p0160"><bold>Toshihide Yokoyama:</bold> Investigation, Writing&#8212;review and editing.</p><p id="p0165"><bold>Naoko Shimada:</bold> Investigation, Writing&#8212;review and editing.</p><p id="p0170"><bold>Tadashi Maeda:</bold> Investigation, Writing&#8212;review and editing.</p><p id="p0175"><bold>Akihiro Tamiya:</bold> Investigation, Writing&#8212;review and editing.</p><p id="p0180"><bold>Ayumi Uchiyama:</bold> Investigation, Writing&#8212;review and editing.</p><p id="p0185"><bold>Kazuyoshi Imaizumi:</bold> Investigation, Writing&#8212;review and editing.</p><p id="p0190"><bold>Takayuki Takahama:</bold> Investigation, Writing&#8212;review and editing.</p><p id="p0195"><bold>Terufumi Kato:</bold> Investigation, Writing&#8212;review and editing.</p><p id="p0200"><bold>Hidetoshi Hayashi:</bold> Investigation, Writing&#8212;review and editing.</p><p id="p0205"><bold>Naoko Shiraiwa:</bold> Conceptualization<bold>,</bold> Writing&#8212;review and editing, Project administration, Writing&#8212;original draft.</p><p id="p0210"><bold>Shigeyuki Toyoizumi:</bold> Conceptualization, Writing&#8212;review and editing, Formal analysis.</p><p id="p0215"><bold>Hironori Kikkawa:</bold> Conceptualization, Writing&#8212;review and editing, Writing&#8212;original draft.</p><p id="p0220"><bold>Despina Thomaidou:</bold> Conceptualization, Writing&#8212;review and editing.</p><p id="p0225"><bold>Makoto Nishio:</bold> Writing&#8212;review and editing, Investigation.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>Seto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hayashi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Satouchi</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study</article-title><source>Cancer Sci</source><volume>111</volume><year>2020</year><fpage>3726</fpage><lpage>3738</lpage><pub-id pub-id-type="pmid">32681682</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cas.14576</pub-id><pub-id pub-id-type="pmcid">PMC7540988</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="other" id="sref2"><person-group person-group-type="author"><collab>Japanese Lung Cancer Society</collab></person-group><article-title>Lung Cancer Clinical Practice Guidelines 2021</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.haigan.gr.jp/guideline/2021/1/2/210102070100.html#7-1-4" id="intref0025">https://www.haigan.gr.jp/guideline/2021/1/2/210102070100.html#7-1-4</ext-link></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name name-style="western"><surname>Hida</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nokihara</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kondo</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial</article-title><source>Lancet</source><volume>390</volume><year>2017</year><fpage>29</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">28501140</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(17)30565-2</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name name-style="western"><surname>Peters</surname><given-names>S.</given-names></name><name name-style="western"><surname>Camidge</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>A.T.</given-names></name><etal/></person-group><article-title>Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer</article-title><source>N&#160;Engl J Med</source><volume>377</volume><year>2017</year><fpage>829</fpage><lpage>838</lpage><pub-id pub-id-type="pmid">28586279</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1704795</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Solomon</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Besse</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>T.M.</given-names></name><etal/></person-group><article-title>Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study</article-title><source>Lancet Oncol</source><volume>19</volume><year>2018</year><fpage>1654</fpage><lpage>1667</lpage><pub-id pub-id-type="pmid">30413378</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(18)30649-1</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="other" id="sref6"><person-group person-group-type="author"><collab>Pharmaceuticals and Medical Devices Agency</collab></person-group><article-title>Report on the Deliberation Results (Lorlatinib)</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.pmda.go.jp/files/000228981.pdf" id="intref0030">http://www.pmda.go.jp/files/000228981.pdf</ext-link></element-citation></ref><ref id="bib7"><label>7</label><mixed-citation publication-type="other" id="sref7">Lobrena (lorlatinib). Prescribing information. Pfizer; 2021. XXX. Accessed October 5, 2022.</mixed-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="other" id="sref8"><person-group person-group-type="author"><collab>Pharmaceuticals and Medical Devices Agency</collab></person-group><article-title>New drugs approved in FY 2021</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.pmda.go.jp/files/000246734.pdf" id="intref0035">https://www.pmda.go.jp/files/000246734.pdf</ext-link></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name name-style="western"><surname>Gainor</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Dardaei</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yoda</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer</article-title><source>Cancer Discov</source><volume>6</volume><year>2016</year><fpage>1118</fpage><lpage>1133</lpage><pub-id pub-id-type="pmid">27432227</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-16-0596</pub-id><pub-id pub-id-type="pmcid">PMC5050111</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>F.</given-names></name></person-group><article-title>The resistance mechanisms and treatment strategies for ALK-rearranged non-small cell lung cancer</article-title><source>Front Oncol</source><volume>11</volume><year>2021</year><object-id pub-id-type="publisher-id">713530</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2021.713530</pub-id><pub-id pub-id-type="pmcid">PMC8517331</pub-id><pub-id pub-id-type="pmid">34660278</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(m etheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations</article-title><source>J&#160;Med Chem</source><volume>57</volume><year>2014</year><fpage>4720</fpage><lpage>4744</lpage><pub-id pub-id-type="pmid">24819116</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jm500261q</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>Shaw</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Felip</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>T.M.</given-names></name><etal/></person-group><article-title>Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial</article-title><source>Lancet Oncol</source><volume>18</volume><year>2017</year><fpage>1590</fpage><lpage>1599</lpage><pub-id pub-id-type="pmid">29074098</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(17)30680-0</pub-id><pub-id pub-id-type="pmcid">PMC5777233</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name name-style="western"><surname>Takeyasu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>T.</given-names></name><name name-style="western"><surname>Masuda</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Lorlatinib versus pemetrexed-based chemotherapy in patients with ALK-rearranged NSCLC previously treated with alectinib</article-title><source>JTO Clin Res Rep</source><volume>3</volume><year>2022</year><object-id pub-id-type="publisher-id">100311</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jtocrr.2022.100311</pub-id><pub-id pub-id-type="pmcid">PMC9046446</pub-id><pub-id pub-id-type="pmid">35498380</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name name-style="western"><surname>Shaw</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Chiari</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1&#8211;2 trial</article-title><source>Lancet Oncol</source><volume>20</volume><year>2019</year><fpage>1691</fpage><lpage>1701</lpage><pub-id pub-id-type="pmid">31669155</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(19)30655-2</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>G.Y.</given-names></name><name name-style="western"><surname>Joshipura</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Efficacy of alectinib in patients with ALK-positive NSCLC and symptomatic or large CNS metastases</article-title><source>J&#160;Thorac Oncol</source><volume>14</volume><year>2019</year><fpage>683</fpage><lpage>690</lpage><pub-id pub-id-type="pmid">30529198</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jtho.2018.12.002</pub-id><pub-id pub-id-type="pmcid">PMC6440803</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>Baldacci</surname><given-names>S.</given-names></name><name name-style="western"><surname>Besse</surname><given-names>B.</given-names></name><name name-style="western"><surname>Avrillon</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: results of the IFCT-1803 LORLATU cohort</article-title><source>Eur J Cancer</source><volume>166</volume><year>2022</year><fpage>51</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">35278825</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2022.01.018</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name name-style="western"><surname>Frost</surname><given-names>N.</given-names></name><name name-style="western"><surname>Christopoulos</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kauffmann-Guerrero</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program</article-title><source>Ther Adv Med Oncol</source><volume>13</volume><year>2021</year><object-id pub-id-type="publisher-id">1758835920980558</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1758835920980558</pub-id><pub-id pub-id-type="pmcid">PMC7876585</pub-id><pub-id pub-id-type="pmid">33613692</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name name-style="western"><surname>Felip</surname><given-names>E.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Bearz</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs</article-title><source>Ann Oncol</source><volume>32</volume><year>2021</year><fpage>620</fpage><lpage>630</lpage><pub-id pub-id-type="pmid">33639216</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annonc.2021.02.012</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>P.H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>K.H.</given-names></name><etal/></person-group><article-title>Real-world efficacy and safety of lorlatinib in treating advanced ALK-positive non-small cell lung cancer patients</article-title><source>Anticancer Drugs</source><volume>32</volume><year>2021</year><fpage>1099</fpage><lpage>1104</lpage><pub-id pub-id-type="pmid">34232936</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CAD.0000000000001107</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>S.</given-names></name><name name-style="western"><surname>Albuquerque de Almeida</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ines</surname><given-names>M.</given-names></name><name name-style="western"><surname>Iadeluca</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>M.</given-names></name></person-group><article-title>Matching-adjusted indirect comparisons of&#160;lorlatinib versus chemotherapy for patients with second-line or later anaplastic lymphoma kinase-positive non-small cell lung cancer</article-title><source>Value Health</source><volume>26</volume><year>2023</year><fpage>64</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">35985941</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jval.2022.07.002</pub-id></element-citation></ref></ref-list><sec id="appsec1" sec-type="supplementary-material"><title>Supplementary Data</title><p id="p0240">
<supplementary-material content-type="local-data" id="mmc1" position="float" orientation="portrait"><caption><title>Supplementary Materials</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.pdf" position="float" orientation="portrait"/></supplementary-material>
</p></sec><ack id="ack0010"><title>Acknowledgments</title><p id="p0230">This study was sponsored by Pfizer Inc. Editorial and medical writing support was provided by Alana Dorfstatter, PharmD, on behalf of Clinical Thinking, Inc., and was funded by Pfizer. The construction of the electronic data capture, data management, statistical analysis, and research operation was provided by Mebix as the contract research organization. The authors acknowledge Masayuki Okura, PhD, who provided statistical analysis support on behalf of Pfizer R&amp;D, Tokyo, Japan.</p><sec id="sec6"><title>Data Sharing</title><p id="p0235">Upon request and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions, and exceptions, Pfizer may also provide access to the related individual deidentified participant data. See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.pfizer.com/science/clinical-trials/trial-data-and-results" id="intref0010">https://www.pfizer.com/science/clinical-trials/trial-data-and-results</ext-link> for more information.</p></sec></ack><fn-group><fn id="d35e882"><p id="ntpara0010"><italic toggle="yes">Disclosure:</italic> Dr. Goto has received personal fees from Pfizer and reports having consulting or advisory roles with AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Guardant Health, Illumina, Johnson &amp; Johnson, Kyorin, Merck, Merck Sharp &amp; Dohme, Novartis, Ono Pharmaceutical, Pfizer, Shionogi Pharma, Taiho Pharmaceutical, and Thermo Fisher Scientific. Dr. Kenmotsu reports receiving research funds from <funding-source id="gs1">AstraZeneca KK</funding-source>, <funding-source id="gs2">Eli Lilly KK</funding-source>, <funding-source id="gs3"><institution-wrap><institution-id institution-id-type="doi">10.13039/100016936</institution-id><institution>Loxo Oncology</institution></institution-wrap></funding-source>, <funding-source id="gs4">Novartis Pharma KK</funding-source>, and <funding-source id="gs5"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100013170</institution-id><institution>Ono Pharmaceutical Co., Ltd.</institution></institution-wrap></funding-source>, and honoraria from <funding-source id="gs6"><institution-wrap><institution-id institution-id-type="doi">10.13039/100002429</institution-id><institution>Amgen</institution></institution-wrap></funding-source>, AstraZeneca KK, <funding-source id="gs7"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004326</institution-id><institution>Bayer</institution></institution-wrap></funding-source>, <funding-source id="gs8">Boehringer Ingelheim</funding-source>, <funding-source id="gs9"><institution-wrap><institution-id institution-id-type="doi">10.13039/100002491</institution-id><institution>Bristol Myers Squibb</institution></institution-wrap></funding-source>, <funding-source id="gs10"><institution-wrap><institution-id institution-id-type="doi">10.13039/100010795</institution-id><institution>Chugai Pharmaceutical</institution></institution-wrap></funding-source>, <funding-source id="gs11"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100022274</institution-id><institution>Daiichi Sankyo</institution></institution-wrap></funding-source>, Eli Lilly KK, <funding-source id="gs12"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100004095</institution-id><institution>Kyowa Hakko Kirin</institution></institution-wrap></funding-source> Co., Ltd., <funding-source id="gs13">Merck Biopharma</funding-source>, <funding-source id="gs14"><institution-wrap><institution-id institution-id-type="doi">10.13039/100009947</institution-id><institution>Merck Sharp &amp; Dohme</institution></institution-wrap></funding-source>, Novartis Pharma KK, Ono Pharmaceutical, <funding-source id="gs15"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004319</institution-id><institution>Pfizer</institution></institution-wrap></funding-source>, <funding-source id="gs16"><institution-wrap><institution-id institution-id-type="doi">10.13039/100009954</institution-id><institution>Taiho Pharma</institution></institution-wrap></funding-source>, and <funding-source id="gs17"><institution-wrap><institution-id institution-id-type="doi">10.13039/100008373</institution-id><institution>Takeda</institution></institution-wrap></funding-source>. Dr. Murakami reports having grants commissioned from AstraZeneca, Chugai Pharmaceutical, Daiichi Sankyo, Janssen Pharmaceutical, Merck Sharp &amp; Dohme, Ono Pharmaceutical, Sanofi, and Takeda and receiving honoraria from AstraZeneca and Pfizer. Dr. Kurata has received honoraria from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Chugai Pharmaceutical, Lilly, Merck Sharp &amp; Dohme, Nippon Kayaku, Ono Pharmaceutical, and Pfizer and grants from AstraZeneca, Bristol Myers Squibb, Chugai Pharmaceutical, Merck Sharp &amp; Dohme, <funding-source id="gs18"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004336</institution-id><institution>Novartis</institution></institution-wrap></funding-source>, and Takeda. Dr. Yanagitani reports receiving speaker and lecture fees from AstraZeneca, Bayer Holding Co., Bristol Myers Squibb, Chugai Pharmaceutical Co., Ltd., Eli Lilly, Ono Pharmaceutical, Pfizer, and Takeda and paid expert testimony from Chugai Pharmaceutical Co. Ltd. Dr. Kuyama has received honoraria from Pfizer. Dr. Shimizu has received personal fees from AstraZeneca, Bristol Myers Squibb, Chugai Pharmaceutical, Merck Biopharma, Merck Sharp &amp; Dohme, Ono Pharmaceutical, Pfizer, Taiho Pharmaceutical, and Takeda. Dr. Yokoyama reports receiving research funding from Takeda and honoraria from Chugai Pharmaceutical, Novartis Pharma KK, <funding-source id="gs19"><institution-wrap><institution-id institution-id-type="doi">10.13039/100010793</institution-id><institution>Pfizer Japan</institution></institution-wrap></funding-source>, Inc., and Takeda. Dr. Tamiya has received research fees from BeiGene and Daiichi Sankyo; funding from AstraZeneca; and honoraria from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Chugai Pharmaceutical, Eli Lilly, Kyowa Kirin, Merck Pharma, Merck Sharp &amp; Dohme, Novartis, Ono Pharmaceutical, Pfizer, Taiho, Takeda Pharmaceutical, and Thermo Fisher. Dr. Takahama reports receiving grants from Takeda and personal fees from AstraZeneca, Bayer, Chugai Pharmaceutical, Pfizer, Roche Diagnostics, and Taiho. Dr. Nishio reports receiving grants and/or payment or honoraria from AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo, Eli Lilly and Company, Merck Biopharma, Merck Sharp &amp; Dohme, Novartis, Ono Pharmaceutical, Pfizer, Taiho Pharmaceutical, Takeda, and Teijin Pharma. Dr. Hayashi has received grants and personal fees from AstraZeneca KK, Boehringer Ingelheim Japan, Bristol Myers Squibb, Chugai Pharmaceutical, and Ono Pharmaceutical and personal fees from Eli Lilly Japan KK, Kyorin Pharmaceutical, Merck Biopharma, Merck Sharp &amp; Dohme KK, Novartis Pharmaceuticals KK, Pfizer Japan, Shanghai Haihe Biopharma, and Taiho Pharmaceutical. Ms. Shiraiwa, Mr. Toyoizumi, Dr. Kikkawa, and Ms. Thomaidou are employees of Pfizer and may own stock in Pfizer. Dr. Kato reports receiving honoraria from AstraZeneca, Chugai Pharmaceutical, Daiichi Sankyo, Lilly, Merck BioPharma, and Merck Sharp &amp; Dohme and grants from commissioned/joint research from <funding-source id="gs20"><institution-wrap><institution-id institution-id-type="doi">10.13039/100006483</institution-id><institution>AbbVie</institution></institution-wrap></funding-source>, <funding-source id="gs21"><institution-wrap><institution-id institution-id-type="doi">10.13039/100002429</institution-id><institution>Amgen</institution></institution-wrap></funding-source>, AstraZeneca, Bristol Myers Squibb, Chugai Pharmaceutical, Eli Lilly, Merck Serono, Merck Sharp &amp; Dohme, Novartis, Ono Pharmaceutical, Pfizer, <funding-source id="gs22"><institution-wrap><institution-id institution-id-type="doi">10.13039/100009857</institution-id><institution>Regeneron</institution></institution-wrap></funding-source>, and Taiho Pharmaceutical. The remaining authors declare no conflict of interest.</p></fn><fn id="d35e956"><p id="ntpara0015">Cite this article as: Goto Y, Kenmotsu H, Tamiya M, et&#160;al. A retrospective, multicenter, observational study to evaluate clinical outcomes of lorlatinib after alectinib in patients With <italic toggle="yes">ALK</italic>-positive NSCLC in Japan. <italic toggle="yes">JTO Clin Res Rep.</italic> XXXX;X:XXXXXX.</p></fn><fn id="appsec2" fn-type="supplementary-material"><p id="p0245">Note: To access the supplementary material accompanying this article, visit the online version of the <italic toggle="yes">JTO Clinical and Research Reports</italic> at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.jtocrr.org" id="intref0015">www.jtocrr.org</ext-link> and at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jtocrr.2023.100508" id="intref0020">https://doi.org/10.1016/j.jtocrr.2023.100508</ext-link>.</p></fn></fn-group></back></article></pmc-articleset>